176 related articles for article (PubMed ID: 22570893)
1. Lipid-based formulations of amphotericin B.
Plotnick AN
J Am Vet Med Assoc; 2000 Mar; 216(6):838-41. PubMed ID: 22570893
[No Abstract] [Full Text] [Related]
2. Lipid formulations of polyene antifungal drugs and attenuation of associated nephrotoxicity.
Razzaque MS; Hossain MA; Ahsan N; Taguchi T
Nephron; 2001 Nov; 89(3):251-4. PubMed ID: 11598385
[TBL] [Abstract][Full Text] [Related]
3. Lipid formulations of amphotericin B.
Jones E; Goldman M
Cleve Clin J Med; 1998 Sep; 65(8):423-7. PubMed ID: 9769563
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B colloidal dispersion.
Patel R
Expert Opin Pharmacother; 2000 Mar; 1(3):475-88. PubMed ID: 11249532
[TBL] [Abstract][Full Text] [Related]
5. [Lipid formulations of amphotericin B in the management of invasive fungal infections].
Fohrer C; Nivoix Y; Moulin JC; Marçais A; Herbrecht R
Therapie; 2006; 61(3):235-42. PubMed ID: 16989124
[TBL] [Abstract][Full Text] [Related]
6. [Lipid formulations of amphotericin].
Botero MC; Puentes-Herrera M; Cortés JA
Rev Chilena Infectol; 2014 Oct; 31(5):518-27. PubMed ID: 25491449
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B and its new derivatives - mode of action.
Baginski M; Czub J
Curr Drug Metab; 2009 Jun; 10(5):459-69. PubMed ID: 19689243
[TBL] [Abstract][Full Text] [Related]
8. Nephrotoxicity in the setting of invasive fungal diseases.
Ullmann AJ
Mycoses; 2008; 51 Suppl 1():25-30. PubMed ID: 18471158
[TBL] [Abstract][Full Text] [Related]
9. The lipid formulations of amphotericin B.
Herbrecht R; Natarajan-Amé S; Nivoix Y; Letscher-Bru V
Expert Opin Pharmacother; 2003 Aug; 4(8):1277-87. PubMed ID: 12877636
[TBL] [Abstract][Full Text] [Related]
10. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
11. Nephrotoxicity of different formulations of amphotericin B: summarizing evidence by network meta-analysis.
Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
Clin Infect Dis; 2013 Dec; 57(12):1783-4. PubMed ID: 24140972
[No Abstract] [Full Text] [Related]
12. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting.
Bes DF; Rosanova MT; Sberna N; Arrizurieta E
Pediatr Infect Dis J; 2014 Aug; 33(8):e198-206. PubMed ID: 24618932
[TBL] [Abstract][Full Text] [Related]
13. A comparative review of conventional and lipid formulations of amphotericin B.
Robinson RF; Nahata MC
J Clin Pharm Ther; 1999 Aug; 24(4):249-57. PubMed ID: 10475983
[TBL] [Abstract][Full Text] [Related]
14. Injectable amphotericin B: mix-ups between lipid and non-lipid formulations.
Prescrire Int; 2009 Dec; 18(104):258-60. PubMed ID: 20025095
[TBL] [Abstract][Full Text] [Related]
15. Is liposomal amphotericin B really safety in neonates?
Karadag-Oncel E; Ozsurekci Y; Yurdakok M; Kara A
Early Hum Dev; 2013 Jan; 89(1):35-6. PubMed ID: 22877627
[No Abstract] [Full Text] [Related]
16. Lipid complexes of amphotericin B: the competitive picture.
Richardson MD
J Med Microbiol; 1997 Mar; 46(3):185-7. PubMed ID: 9126817
[No Abstract] [Full Text] [Related]
17. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis.
Thornton SJ; Wasan KM
Expert Opin Drug Deliv; 2009 Mar; 6(3):271-84. PubMed ID: 19327044
[TBL] [Abstract][Full Text] [Related]
18. Response to "is liposomal amphotericin B really safety in neonates?".
Manzoni P; Rizzollo S; Farina D
Early Hum Dev; 2013 Jan; 89(1):37. PubMed ID: 22831635
[No Abstract] [Full Text] [Related]
19. Amphotericin B lipid preparations: what are the differences?
Adler-Moore JP; Proffitt RT
Clin Microbiol Infect; 2008 May; 14 Suppl 4():25-36. PubMed ID: 18430127
[TBL] [Abstract][Full Text] [Related]
20. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis.
Mistro S; Maciel Ide M; de Menezes RG; Maia ZP; Schooley RT; Badaró R
Clin Infect Dis; 2012 Jun; 54(12):1774-7. PubMed ID: 22491505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
